WO1991015584A1 - Peptides recombinants et synthetiques de trypanosoma cruzi utilises pour le diagnostic immunologique de la maladie de chagas - Google Patents
Peptides recombinants et synthetiques de trypanosoma cruzi utilises pour le diagnostic immunologique de la maladie de chagas Download PDFInfo
- Publication number
- WO1991015584A1 WO1991015584A1 PCT/BR1991/000003 BR9100003W WO9115584A1 WO 1991015584 A1 WO1991015584 A1 WO 1991015584A1 BR 9100003 W BR9100003 W BR 9100003W WO 9115584 A1 WO9115584 A1 WO 9115584A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alanine
- arginine
- glutamic acid
- leucine
- lysine
- Prior art date
Links
- 241000223109 Trypanosoma cruzi Species 0.000 title claims abstract description 23
- 239000000427 antigen Substances 0.000 title claims abstract description 18
- 108091007433 antigens Proteins 0.000 title claims abstract description 18
- 102000036639 antigens Human genes 0.000 title claims abstract description 18
- 206010001935 American trypanosomiasis Diseases 0.000 title claims abstract description 13
- 208000024699 Chagas disease Diseases 0.000 title claims abstract description 12
- 238000003745 diagnosis Methods 0.000 title claims abstract description 11
- 230000001900 immune effect Effects 0.000 title claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract 30
- 235000004279 alanine Nutrition 0.000 claims abstract 30
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract 24
- 235000013922 glutamic acid Nutrition 0.000 claims abstract 24
- 239000004220 glutamic acid Substances 0.000 claims abstract 24
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract 23
- 239000004475 Arginine Substances 0.000 claims abstract 20
- 235000009697 arginine Nutrition 0.000 claims abstract 20
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 20
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract 16
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract 16
- 239000004472 Lysine Substances 0.000 claims abstract 16
- 235000005772 leucine Nutrition 0.000 claims abstract 16
- 235000018977 lysine Nutrition 0.000 claims abstract 16
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract 15
- 235000003704 aspartic acid Nutrition 0.000 claims abstract 15
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract 15
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract 13
- 235000004554 glutamine Nutrition 0.000 claims abstract 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract 8
- 235000013930 proline Nutrition 0.000 claims abstract 8
- 235000014393 valine Nutrition 0.000 claims abstract 8
- 239000004474 valine Substances 0.000 claims abstract 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract 6
- 235000006109 methionine Nutrition 0.000 claims abstract 6
- 229930182817 methionine Natural products 0.000 claims abstract 6
- 235000004400 serine Nutrition 0.000 claims abstract 6
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract 5
- 150000001413 amino acids Chemical group 0.000 claims abstract 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract 4
- 235000009582 asparagine Nutrition 0.000 claims abstract 4
- 229960001230 asparagine Drugs 0.000 claims abstract 4
- 235000008729 phenylalanine Nutrition 0.000 claims abstract 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000004473 Threonine Substances 0.000 claims abstract 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004717 insulin aspart Drugs 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- -1 isoiencine Chemical compound 0.000 claims 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 abstract description 3
- 238000001262 western blot Methods 0.000 abstract description 3
- 230000004520 agglutination Effects 0.000 abstract description 2
- 230000035931 haemagglutination Effects 0.000 abstract description 2
- 229960003767 alanine Drugs 0.000 abstract 16
- 229960002989 glutamic acid Drugs 0.000 abstract 12
- 229960003121 arginine Drugs 0.000 abstract 10
- 229960005261 aspartic acid Drugs 0.000 abstract 8
- 229960003136 leucine Drugs 0.000 abstract 8
- 229960003646 lysine Drugs 0.000 abstract 8
- 229960002743 glutamine Drugs 0.000 abstract 5
- 229960002429 proline Drugs 0.000 abstract 4
- 229960004295 valine Drugs 0.000 abstract 4
- 229960001153 serine Drugs 0.000 abstract 3
- 229960004452 methionine Drugs 0.000 abstract 2
- 229960005190 phenylalanine Drugs 0.000 abstract 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- 235000014705 isoleucine Nutrition 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 238000003127 radioimmunoassay Methods 0.000 abstract 1
- 244000045947 parasite Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This patent request refers to the use of Trypanosoma cruzi repetitive recombinant antigens, as well as the corresponding synthetic peptides, in the immunological detection of Chagas Disease and its ethiological agent, the parasite Trypanosoma cruzi.
- the immunological diagnosis of Chagas Disease is in general based on the use of crude or semi-purified parasite extracts for the detection of antibodies, in different tests such as hemagglutination, ELISA, rad i o i mmunoassay and Western blot analysis.
- hemagglutination ELISA
- rad i o i mmunoassay Western blot analysis.
- it is generally observed the cross-reactivity with patients bearing other diseases such as visceral and tegumentar leishmaniasis, toxoplasmosis, syphilis and schistosomiasis,
- the use of parasite extracts involves some rises for its preparation and is relatively expensive.
- T.cruzi DNA was cloned in E.coli using the expression vector lambda gt11, and the recombinant clones were screened with a pool of human chagasic sera. Twelve recombinant clones were purified to homogeneity and from these two were selected on the basis of the specificity of their reactivity with chagasic sera. Partial nucleotide sequence of these clones showed that one of them (Ag#1) encodes an antigen composed of at least 23 repetitions of a 14 aminoacids motif whereas the other (Ag#2) encodes an antigen containing at least 14 repetitions of a 68 am i noac i ds repetitive epitope.
- Ag#1 encodes an antigen composed of at least 23 repetitions of a 14 aminoacids motif
- Ag#2 encodes an antigen containing at least 14 repetitions of a 68 am i noac i ds repetitive epitope.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention se rapporte à l'utilisation d'antigènes de Trypanosoma cruzi, qu'on obtient en utilisant des techniques d'ADN recombinant, ou à des peptides synthétiques tirés de ces antigènes, ainsi qu'à leur utilisation dans le diagnostic immunologique de la maladie de Chagas soit au moyen du test ELISA soit au moyen des tests dits ''western blot'' ou ''dot-blot'' soit au moyen des techniques de l'hémagglutination ou de l'agglutination soit au moyen d'anticorps monoclonaux ou d'une radioimmunoanalyse. Ces antigènes ou ces peptides synthétiques se caractérisent en ce qu'ils présentent les séquences d'acides aminés suivantes: Ag1: valine(ou alanine), alanine, acide glutamique, alanine (ou thréonine), acide glutamique, lysine, glutamine, lysine (ou arginine), alanine, alanine, acide glutamique, alanine (ou sérine), thréonine (ou méthionine ou alanine) et lysine; Ag2: méthionine, acide glutamique, glutamine, acide glutamique, arginine, arginine, glutamine, leucine, leucine, acide glutamique, lysine, acide aspartique, proline, arignine, arginine, asparagine, alanine, lysine, acide glutamique, isoleucine, alanine, alanine, leucine, acide glutamique, acide glutamique, sérine, méthionine, asparagine, alanine, arginine, alanine, glutamine, acide glutamique, leucine, alanine, arginine, acide glutamique, lysine, lysine, leucine, arginine, acide aspartique, arginine, alanine, phénylalanine, leucine, acide aspartique, glutamine, lysine, proline, acide glutamique, arginine, valine, proline, leucine, alanine, acide aspartique, valine, proline, leucine, acide aspartique, acide aspartique, acide aspartique, sérine, acide aspartique, phénylalanine, valine et alanine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR909001479A BR9001479A (pt) | 1990-03-30 | 1990-03-30 | Antigenos de trypanosoma cruzi,assim como polipeptideos sinteticos,para utilizacao no diagnostico da doenca de chagas |
| BR9001479 | 1990-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991015584A1 true WO1991015584A1 (fr) | 1991-10-17 |
Family
ID=4049195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR1991/000003 WO1991015584A1 (fr) | 1990-03-30 | 1991-04-01 | Peptides recombinants et synthetiques de trypanosoma cruzi utilises pour le diagnostic immunologique de la maladie de chagas |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0486627A1 (fr) |
| BR (1) | BR9001479A (fr) |
| WO (1) | WO1991015584A1 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992009895A1 (fr) * | 1990-11-28 | 1992-06-11 | Fundação Oswaldo Cruz (Fiocruz) - Superintendência De Planejamento | Composition comprenant des antigenes conjugues a une activite enzymatique, et destinee aux necessaires a usage prive et epidemiologique de diagnostic immunologique, notamment de la maladie de chagas, et procede de preparation de ladite composition |
| FR2692900A1 (fr) * | 1992-06-25 | 1993-12-31 | Pasteur Institut | Séquence peptidique inductrice d'une protection contre une infection par T. cruzi; applications diagnostiques et thérapeutiques. |
| US5876734A (en) * | 1994-03-24 | 1999-03-02 | Kirchhoff; Louis V. | Polypeptides for diagnosing infection with Trypanosoma cruzi |
| US7749717B2 (en) | 2006-10-19 | 2010-07-06 | Abbott Laboratories | Methods for the detection and diagnosis of Trypanosoma cruzi infection |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0003529A1 (fr) * | 1978-01-25 | 1979-08-22 | The Wellcome Foundation Limited | Antigènes de Trypanosoma cruzi, leur purification et leur utilisation dans des vaccins |
| DE3012204A1 (de) * | 1979-03-29 | 1980-10-23 | Wellcome Found | Antigen, verfahren zu seiner herstellung und seine verwendung |
| EP0138101A1 (fr) * | 1983-09-30 | 1985-04-24 | Rockefeller University | Organisme préparé par technologie génétique exprimant les protéines de surface de T. Cruzi |
| EP0273555A2 (fr) * | 1986-11-04 | 1988-07-06 | Codon | Matériau antigène pour un système de détection de la maladie de chagas |
-
1990
- 1990-03-30 BR BR909001479A patent/BR9001479A/pt not_active Application Discontinuation
-
1991
- 1991-04-01 EP EP91906678A patent/EP0486627A1/fr not_active Withdrawn
- 1991-04-01 WO PCT/BR1991/000003 patent/WO1991015584A1/fr not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0003529A1 (fr) * | 1978-01-25 | 1979-08-22 | The Wellcome Foundation Limited | Antigènes de Trypanosoma cruzi, leur purification et leur utilisation dans des vaccins |
| DE3012204A1 (de) * | 1979-03-29 | 1980-10-23 | Wellcome Found | Antigen, verfahren zu seiner herstellung und seine verwendung |
| EP0138101A1 (fr) * | 1983-09-30 | 1985-04-24 | Rockefeller University | Organisme préparé par technologie génétique exprimant les protéines de surface de T. Cruzi |
| EP0273555A2 (fr) * | 1986-11-04 | 1988-07-06 | Codon | Matériau antigène pour un système de détection de la maladie de chagas |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992009895A1 (fr) * | 1990-11-28 | 1992-06-11 | Fundação Oswaldo Cruz (Fiocruz) - Superintendência De Planejamento | Composition comprenant des antigenes conjugues a une activite enzymatique, et destinee aux necessaires a usage prive et epidemiologique de diagnostic immunologique, notamment de la maladie de chagas, et procede de preparation de ladite composition |
| FR2692900A1 (fr) * | 1992-06-25 | 1993-12-31 | Pasteur Institut | Séquence peptidique inductrice d'une protection contre une infection par T. cruzi; applications diagnostiques et thérapeutiques. |
| US5876734A (en) * | 1994-03-24 | 1999-03-02 | Kirchhoff; Louis V. | Polypeptides for diagnosing infection with Trypanosoma cruzi |
| US6228601B1 (en) | 1994-03-24 | 2001-05-08 | Louis V. Kirchhoff | Polypeptides for diagnosing infection with trypanosoma cruzi |
| US7749717B2 (en) | 2006-10-19 | 2010-07-06 | Abbott Laboratories | Methods for the detection and diagnosis of Trypanosoma cruzi infection |
Also Published As
| Publication number | Publication date |
|---|---|
| BR9001479A (pt) | 1991-04-16 |
| EP0486627A1 (fr) | 1992-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2675009B2 (ja) | 改良ペプチド組成物およびｈｉｖに対する抗体の検出方法 | |
| EP0683234B2 (fr) | Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation | |
| US5955317A (en) | Antibodies to β-amyloids or their derivatives and use thereof | |
| US5756662A (en) | Compounds and methods for the detection of T. cruzi infection | |
| PT941244E (pt) | Péptido derivados de um antigénio reconhecido por autoanticorpos de pacientes com artrite reumatóide, anticorpo dirigido contra o referido péptido e método de detecção de anticorpos auto-imunes | |
| JPH07260783A (ja) | 口蹄疫ビールスの抗原活性を有するカタマー | |
| AU7234387A (en) | Synthetic htlv-iii peptides, compositions and uses thereof | |
| PT1881064E (pt) | Anticorpo monoclonal anti-núcleo de hcv | |
| CA2391356A1 (fr) | Peptides permettant de diagnostiquer et de traiter la polyarthrite rhumatoide | |
| EP1155322B1 (fr) | Composes et methodes pour detecter une infection par trypanosoma cruzi | |
| Teisner et al. | Fetal antigen 2: an amniotic protein identified as the aminopropeptide of the α1 chain of human procollagen type I | |
| JP2643598B2 (ja) | Ｈｔｌｖ‐▲ｉ▼抗体に対する免疫反応性を有する合成ペプチド組成物 | |
| WO1997018475A1 (fr) | Composes et procedes de detection et de prevention d'infections par t. cruzi | |
| Fujii et al. | Localization of biologically uncommon D-beta-aspartate-containing alphaA-crystallin in human eye lens | |
| WO1991015584A1 (fr) | Peptides recombinants et synthetiques de trypanosoma cruzi utilises pour le diagnostic immunologique de la maladie de chagas | |
| EP0386166A1 (fr) | ANTICORPS IgM REAGISSANT A LA PROTAMINE. | |
| Lowey et al. | Neonatal and adult myosin heavy chains form homodimers during avian skeletal muscle development. | |
| RU2001127439A (ru) | Пептиды из последовательности Т-вируса и моноспецифические антитела, связывающиеся с ТТ-вирусом | |
| WO1999031246A1 (fr) | COMPOSITIONS ET PROCEDES DE DETECTION D'INFECTIONS PAR LE $i(TRYPANOSOMA CRUZI) | |
| US20060211056A1 (en) | Leishmania antigens suitable for a diagnostic kit of Leishmania | |
| Clarke et al. | Structural features of antigenic determinants on variant surface glycoproteins from Trypanosoma brucei | |
| Richman et al. | Peptide mapping of conformational epitopes in a human malarial parasite heat shock protein. | |
| JP4568842B2 (ja) | 熱帯熱マラリア原虫のエノラーゼ蛋白質の部分ペプチドの製造方法 | |
| CN115015545B (zh) | 基于壳多糖酶3样蛋白1的高灵敏度肝病检测试剂盒 | |
| Nagy et al. | Immunogenicity of a unique region of the human thyrotropin receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1991906678 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1991906678 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1991906678 Country of ref document: EP |